Browse recruiting and upcoming clinical trials for splenic marginal zone lymphoma.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this listHide
ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Who can join AIPeople with relapsed or refractory B-cell non-Hodgkin lymphomas (including CLL/SLL, DLBCL, follicular, marginal-zone, and mantle cell lymphoma).
What is being studied AITests combining the drugs zanubrutinib and sonrotoclax for relapsed or refractory B‑cell NHL.
Who can join AIPeople with relapsed or refractory B‑cell non-Hodgkin lymphoma, including DLBCL, follicular, mantle cell, marginal zone, and Waldenstrom macroglobulinemia.
What is being studied AITests a single IV infusion of SynKIR-310 (autologous T cells transduced with CD19 KIR‑CAR).
Who can join AIPeople with indolent B‑cell non‑Hodgkin lymphomas such as mantle cell, follicular, splenic or nodal marginal zone, and extranodal (MALT) lymphoma.
What is being studied AITests safety, tolerability, and anti-tumor activity of kappa-targeted CAR T cells.
Who can join AIPeople being evaluated for a hematologic cancer or related blood or lymphoid disorder (leukemia, lymphoma, multiple myeloma, myelodysplastic and myeloproliferative disorders, and related neoplasms) at the University of North Carolina Hospitals — in the hematology/oncology clinics, the stem cell transplant clinic, or as an inpatient.
What is being studied AICollects and stores blood, tissue, and body-fluid samples for future laboratory research.
Trials that may include splenic marginal zone lymphoma (1)
ClinicalTrials.gov returned these when we searched for this condition, but we could not confirm from the registry records that they are intended for people with it. Check each trial’s eligibility criteria, and ask the study team if you are unsure.